Agents that interfere with GM-CSF action have been suggested to reduce the inflammatory response and prevent lung injury in severe COVID-19 patients [48,79]. A monoclonal neutralizing antibody against GM-CSF, lenzilumab, has been reported to improve survival in ventilator-free patients in a multicenter RCT [80]. Here, CSF2 is linked to COVID-19.